The National Health Surveillance Agency (ANVISA) has determined the seizure of counterfeit medications intended for the Brazilian pharmaceutical market. The action, resulting from inspection and sanitary surveillance, identified irregular products in the categories of breast cancer medications and botulinum toxin.
The measure reinforces the regulatory agency's commitment to protecting public health and ensuring the quality of medications available to the population. Counterfeit medications pose significant risks to consumers, including possible variations in composition, inadequate concentration of active ingredients, and contamination that may compromise treatment efficacy and safety.
ANVISA continues to exercise its surveillance function over the pharmaceutical chain, investigating irregularities and applying administrative measures when necessary. The seizure is part of routine inspection operations aimed at combating medication counterfeiting in the country.
Consumers and healthcare professionals are advised to verify the origin and authenticity of medications by consulting ANVISA's registry through its official portal. Medication purchases should occur exclusively at legalized and authorized pharmacies.
This action demonstrates the importance of the pharmaceutical regulatory system in identifying and eliminating products that do not meet the quality and safety standards established by Brazilian legislation. ANVISA maintains permanent surveillance over the pharmaceutical market to protect the population from risks associated with irregular medications.
